GSK-J4 is a selective JMJD3/UTX inhibitor that triggers the enrichment of H3K27me3 in cell line models [12] and is suggested as a potential treatment option in the acute lymphoblastic leukaemia [13] and brainstem glioma [14]. The gene discussed is KDM6A; the disease is brain stem glioma.